Group 1: Core Insights - UBS's in-depth research in China identifies two main industry themes for 2026: self-sufficiency and overseas expansion [1] - The research covered various sectors including technology, industrial, healthcare, consumer, and utilities, visiting over 100 companies and industry experts [1] - The report highlights a shift in investor interest, with capital goods, media entertainment, and real estate development seeing increased research focus, while semiconductor and automotive parts sectors experienced a decline [1] Group 2: Technology Sector Insights - The technology sector is a key focus, with advancements in self-sufficiency moving from isolated breakthroughs to industry-wide collaboration [2] - AI capital expenditure is expected to grow steadily in 2026, driven by strong demand for AI applications and local semiconductor production [3] - Despite uncertainties regarding H200 GPU imports, domestic supply chains are adapting through technology substitution and demand upgrades [3] Group 3: Semiconductor Developments - The localization of China's semiconductor industry is accelerating, with significant progress in advanced etching/ deposition equipment, advanced packaging, and high-end analog chips [4] - Capital expenditure for wafer fabrication equipment (WFE) is projected to grow by 10-15% annually, driven by capacity expansion in advanced logic and memory wafer fabs [4] - Domestic manufacturers anticipate a substantial increase in storage capital expenditure in 2026, aligning with a global upcycle in the storage industry [4] Group 4: Overseas Expansion Trends - Multiple industries, including industrial, biopharmaceuticals, and consumer goods, are focusing on overseas expansion as a key growth strategy [6] - In the industrial sector, overseas orders for AIDC and renewable energy storage equipment are increasing significantly [7] - The healthcare sector is also prioritizing global expansion, with biopharmaceutical companies actively pursuing international collaborations and local sales team development [9] Group 5: Key Recommendations - UBS recommends several core stocks in the technology and semiconductor sectors, including Northern Huachuang (advanced etching/ deposition), Changdian Technology (advanced packaging), and Horizon Robotics (edge AI) [5][12] - In the healthcare sector, companies like WuXi AppTec (CRO/CDMO) and 3SBio (biopharmaceuticals) are highlighted as key beneficiaries of global expansion [12] - The consumer sector sees recommendations for Jason Furniture (overseas expansion) and Leap Motor (new energy vehicles), while Gree Electric Appliances is advised to sell due to margin pressures [12] Group 6: Overall Industry Outlook - The report concludes that China's industrial development in 2026 will be characterized by a dual focus on self-sufficiency in technology and overseas expansion in various sectors [13] - The integration of these two themes is expected to enhance China's economic globalization, with technology supporting overseas expansion and vice versa [13] - Investment opportunities are identified in sectors with low crowding and improving fundamentals, as well as in high-growth areas like AI and semiconductors [13]

Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry by leveraging strong technological capabilities and strategic focus, aiming to enhance its competitiveness and market penetration in the regenerative medicine sector [1][10]. Group 1: Company Overview - He Yuan Bio, founded in 2013, specializes in providing integrated CRO/CDMO services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1][2]. - As the first CGT company listed on the Sci-Tech Innovation Board, He Yuan Bio has been pivotal in the transition of China's biopharmaceutical industry from a follower to a leader [1]. Group 2: Technological Innovation - The company has made significant investments in R&D, with R&D expenses reaching 34.66 million yuan in the first three quarters of 2025, accounting for 19.22% of its revenue [3]. - He Yuan Bio has established comprehensive technology platforms, including molecular biology, virus packaging, and cell function research, achieving leading levels in key areas such as viral vector technology [2][3]. - The integration of AI technology into drug development processes has been a focus, with the establishment of an intelligent R&D system that enhances efficiency [4]. Group 3: Market Position and Client Base - He Yuan Bio has built a robust client base, collaborating with over 14,700 research laboratories and managing more than 600 CDMO projects, including five Phase III clinical projects [5]. - The company emphasizes the importance of deep technical insights and precise control over process details as core values in its CRO and CDMO services [5]. Group 4: Future Development and Expansion - The company is expanding into the regenerative medicine sector by establishing a wholly-owned subsidiary, He Yuan He Mei, to address challenges in cell safety and traceability [8]. - The company’s production base in Lingang has commenced operations, featuring 11 GMP vector production lines and 18 GMP cell production lines, positioning it among the top in the international industry [6]. - He Yuan Bio aims to enhance its international presence by supporting domestic clients in obtaining overseas IND approvals and facilitating the licensing of proprietary technologies [9]. Group 5: Commitment to Health and Innovation - The company is committed to empowering cell and gene therapy to improve public health, focusing on innovation and collaboration to drive high-quality development in the CGT field [10].

站在生物医药创新的前沿，细胞和基因治疗（CGT）行业有着非常高的技术壁垒，但总有一些企业凭借 坚定的战略定力和强大的技术实力，穿越行业周期，实现跨越式发展。 作为登陆科创板的CGT第一股，和元生物深耕细胞与基因治疗领域十余年，自主研发形成细胞和基因治 疗载体开发技术、细胞和基因治疗载体生产工艺及质控技术两大核心技术集群，布局了前沿的质粒、免 疫细胞、干细胞、病毒、mRNA、外泌体等相关的技术和工艺，从基础底层技术和产业化技术层面解决 瓶颈问题。 "公司积极拥抱变革，在AI应用领域展开不少探索，相继构建智能研发体系、AI模型等，推动研发、生 产效率提升。"和元生物副总经理、董事会秘书徐鲁媛表示，"我们通过人工智能与生物技术的结合，已 经形成了'算法创新+应用落地'的双轮驱动模式。在研发设计与检测工具开发方面，公司已打通AI与生 产数据链路，打造'智能设计-模型搭建-算法验证-大数据反馈'的智能研发体系。" "未来我们将进一步加强技术硬实力，保持行业领先地位，提升自身核心竞争力。"徐鲁媛称。 提升CGT药物商业可及性 "和元生物的发展始终跟随中国生物医药产业从'跟跑'到'领跑'的时代步伐，逐步成长为细分行业领军 ...

看好医药"四重共振"投资机会 20251204 摘要 医药板块在 2025 年虽有修复，但未成市场主线，申万医药生物指数排 名靠后。经历四年调整后，板块已显现反弹迹象，预计 2026 年仍有上 涨空间，当前调整主因资金面，而非基本面恶化，提供布局良机。 2025 年医药行业经历多波行情，包括春节后的估值修复、3 月医药会议 数据超预期，以及 4 月地缘政治冲击后的创新药韧性。二季度末至三季 度初出现回调，但整体基于资金面，当前是布局医药股的良好时机。 当前最看好创新药、医疗器械和 CRO/CDMO 服务三条主线。创新药作 为排头兵，催化剂多且确定性高，估值逐步稳定；医疗器械受益于技术 进步和需求增长，发展潜力巨大；CRO/CDMO 服务受益于全球制药外 包需求增加。 转型老药企在创新药领域表现出色，拥有稳定收入和业绩作为估值参考， 估值重塑进行中，研发能力逐渐被市场认可，且在国际化方面展现出潜 力，BD 方面具有未被充分定价的潜力。 创新药投资具有临床试验时间点和数据确定性提高的特点。公司临床经 验和平台成熟度提升，监管审批时间缩短，临床数据预测更准确，同类 产品数据提供参考，核心管线数据波动减少。 Q&A ...

Core Insights - The article discusses the successful completion of the "Pudong Science and Technology Innovation - Haiwang Summit (Phase II) CEO Training Camp," which gathered over thirty technology entrepreneurs in Shanghai for a two-day learning experience [3][10] - The training focused on strategic management and product development, providing practical insights and frameworks for entrepreneurs to navigate complex environments and achieve sustainable growth [3][4] Group 1: Strategic Management - Expert Chen Zhuyou emphasized the importance of forward-thinking strategic thinking for long-term development in a complex environment, highlighting the need for multi-layered analysis of macro, meso, and micro environments [4][5] - He discussed the limitations of homogeneous competition and advocated for differentiation, specialization, and cognitive competition to gain a competitive edge [4] - The course provided strategic tools and frameworks to help entrepreneurs enhance competitiveness during the transition from old to new growth drivers [4][6] Group 2: Product Development - Zhang Shanfeng, Chairman of Guokewanhua, focused on key aspects of product development management for startups, stressing the importance of engineering and user orientation for product success [5][6] - He highlighted the need for clear product hierarchy and business models, focusing on core users and standardizing product documentation as essential steps for startups to mature [5][6] - The value of AI in improving research efficiency and optimizing documentation and processes was also emphasized, along with the importance of data security and private deployment [6] Group 3: Practical Experience - The training included a visit to He Yuan Biotechnology (Shanghai) Co., Ltd., a high-tech enterprise listed on the Sci-Tech Innovation Board, which specializes in cell and gene therapy [8][10] - Xu Luyuan, Deputy General Manager and Board Secretary of He Yuan Biotechnology, provided insights into the company's development history, core technological capabilities, and practical advice for startups facing challenges in development and technology transfer [10] - The visit allowed participants to gain a more intuitive understanding of industry innovation models and operational management through direct interaction [10]

Group 1 - The core viewpoint is that He Yuan Bio is experiencing sustained policy support in the cell and gene therapy (CGT) sector, with indications expanding from tumors to multiple areas, despite a cautious investment environment [1] - The company's CDMO business is affected by a slowdown in investment, leading to short-term fluctuations in gross margin, but the long-term market potential remains significant, with gross margins expected to gradually recover [1] - The CRO business is showing steady growth, with an 8.02% increase in sales revenue and an expanding customer base, while actively exploring overseas markets [1] Group 2 - In the fourth quarter, sales and management expenses increased while R&D expenses decreased, with plans for multiple quality improvement measures in 2025 [1] - He Yuan Bio has established a wholly-owned subsidiary, He Yuan He Mei, in the field of regenerative medicine to achieve large-scale cell production and expand its CRO/CDMO full industry chain services [1] - The company has signed new orders exceeding 270 million, and the GMP capacity utilization rate at the Lingang industrial base continues to improve [1] Group 3 - The company aims to optimize its business model centered around underlying technology, expand into international markets, and strengthen strategic partnerships, aspiring to become a comprehensive service platform in the fields of cell gene therapy and regenerative medicine, with a focus on both domestic and global markets [1]